Business Information
The group's principal activity is to develop, manufacture and market a broad range of innovative products to improve human and animal health. The products of the group are sold primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and health care providers such as health maintenance organizations and other institutions. Some of the important products of the group include arcoxia, cancidas, comvax, cosopt, cozaar, crixivan, emend, fosamax, hyzaar, invanz, maxalt, pedvaxhib, primaxin, propecia, proscar, recombivax hb, singulair, timoptic-xe , trusopt, vioxx and zocor. The group has operations in the United States, Europe, Middle East, Africa and Japan. In mar 2004, the group acquired aton pharma inc and banyu pharmaceutical co ltd.
|
|
Name |
Title
|
Email
|
| Raymond Gilmartin | Chmn., CEO, Pres. | N/A | | Richard Clark | Chmn., CEO, Pres. | N/A | | Adel Mahmoud | Pres. - Merck Vaccine Division | N/A | | Bradley Sheares | Pres. - US Human Health | N/A | | Margaret McGlynn | Pres. - Merck Vaccine Division, Pres. - US Human Health | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 22,636,000 | 4,433,800 | | 2005 | 22,011,900 | 4,631,300 | | 2004 | 22,938,600 | 5,813,400
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
